How to Buy Amedisys Stock
Amedisys Inc
Amedisys, Inc. , together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care.
Amedisys stock last closed at $91.76, down 0.16% from the previous day, and has increased 0.88% in one year. It has overperformed other stocks in the Medical Care Facilities industry by 0.06 percentage points. Amedisys stock is currently +11.7% from its 52-week low of $82.15, and -7.27% from its 52-week high of $98.95.
As of Apr 17, 2025, there are 38.37M shares of AMED outstanding. The market cap of AMED is $3.52B. In the last 24 hours, 133,860 AMED shares were traded.
How to Buy Amedisys Stock
Not sure how to invest in Amedisys stock? Here's how.
- Decide where to buy Amedisys stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you decide where to buy Amedisys stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your investment account: Choose your method of payment and add your information.
- Analyze Amedisys stock: The Amedisys ticker symbol is AMED. Is Amedisys stock a good investment? Should you buy shares of AMED? How do AMED's underlying business fundamentals look? Do top analysts think Amedisys is a good buy? Why has AMED's stock price moved recently? (Hint: Our stock research tools can help you figure out if AMED is a good stock to buy).
- Make your AMED purchase: Decide if you will purchase AMED shares at the current market price or use a limit order to purchase AMED stock at a specific price.
- Get the latest scoop on your AMED investment: Create a watchlist to monitor your position in Amedisys shares.
Step 1: Decide where to buy Amedisys stock
You will need an online brokerage account to access the NASDAQ market and buy AMED stock.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global financial markets: From Technology to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked your brokerage, it's time to fill out some personal information so you can invest in AMED stock today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to create your new trading account.
- Submit your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have finished signing up on the best stock trading app, you can securely and quickly fund your account:
Check out the video below to see the process of depositing money into your new brokerage account.
Step 4: Analyze Amedisys stock
After you have selected the best place to buy Amedisys stock, it's absolutely critical to analyze their stock before you buy, so you can understand the risk as well as the opportunity.
Amedisys Numbers
AMED Due Diligence Checks
WallStreetZen was created to help part-time investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on AMED's stock page.
Is AMED stock overvalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge AMED's true value.
Using relative valuations methods:
- AMED could be overvalued based on its P/E ratio of 69.52x, relative to Medical Care Facilities industry P/E ratio of 14.77x
- AMED could be undervalued based on its P/B ratio of 3.1x, relative to Medical Care Facilities industry P/B ratio of 4.22x
- AMED could be undervalued based on its PEG ratio of 0.33x
You can access additional valuation research on AMED's stock here.
AMED Financial Health Summary
Passed Financial Due Diligence Checks:
- There are more short-term assets than long-term liabilities on the AMED balance sheet.
- There are more short-term assets than short-term liabilities on the AMED balance sheet.
- Total AMED debt is lower than 5 years ago, relative to shareholder equity.
- AMED's operating cash flow of $221.67M allows it to safely service it's debt of $459.30M.
- AMED profit margin has gone up from -0.4% to 1.8% in the past year.
Failed Financial Due Diligence Checks:
- AMED earnings of $122.05M is not sufficient to cover its interest payments.
- AMED has a relatively high debt to equity ratio of 0.85.
Is Amedisys stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 3 Wall Street analysts who give ratings on AMED, the consensus analyst rating on Amedisys is a Hold
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are forecasting on the Amedisys stock forecast page.
AMED Technicals
AMED Growth Numbers
Last year, AMED earnings were $43.23M. In the last 5 year, AMED's earnings have grown by -19.69% per year. This was slower than the Medical Care Facilities industry average of 14.68%.
Last year, AMED revenue was $2.35B. During the past five year, AMED's revenue has grown by 3.73% per year. This was slower than the Medical Care Facilities industry average of 8.11%.
Dive into AMED's earnings and revenue performance here.
What are AMED insiders up to?
Over the last 12 months, insiders at AMED have sold more shares than they have bought.
Allyson Guidroz, Chief Accounting Officer of AMED, was the latest AMED insider to sell. They sold $187,833.23 worth of AMED shares on Mar 4, 2025.
Research more about who owns AMED shares here.
Does AMED stock generate passive income?
No, Amedisys doesn't provide an income stream by paying out dividends.
What do other investors have to say about AMED?
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your AMED purchase
There are two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually fine for most investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a given dollar amount limit, place a limit order.
Click the Open Trade button and eToro will place your order.
If you require additional info about investing in stocks on eToro, click the how to video below:
Step 6: Get the latest scoop on your AMED investment
Now that you own some shares in AMED, you'll want to stay up-to-date on your investment.
Make a watchlist to keep track of your AMED stock.
AMED Feed
How to Buy Stock in Amedisys
To reiterate, here are the 6 steps for buying Amedisys stock:
- Decide where to buy Amedisys stock
- Open a brokerage account
- Deposit funds into your investment account
- Analyze Amedisys stock
- Make your AMED purchase
- Get the latest scoop on your AMED investment
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep tabs on your investment in Amedisys, add AMED to your watchlist by clicking the button below.
Related Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.